A randomized placebo‐controlled trial of prophylactic dexamethasone for transcatheter arterial chemoembolization

Sadahisa Ogasawara, Tetsuhiro Chiba, Yoshihiko Ooka, Naoya Kanogawa, Tenyu Motoyama, Eiichiro Suzuki, Akinobu Tawada, Kazue Nagai, Tomoo Nakagawa, Takeshi Sugawara, Hideki Hanaoka, Fumihiko Kanai, Osamu Yokosuka – 26 July 2017 – This randomized, double‐blind, placebo‐controlled trial evaluated dexamethasone efficacy at preventing fever, anorexia, and nausea/vomiting, the most frequent adverse events of transcatheter arterial chemoembolization (TACE) in patients with hepatocellular carcinoma (HCC).

Profiling of the circadian metabolome in thioacetamide‐induced liver cirrhosis in mice

Koichi Fujisawa, Taro Takami, Toshihiko Matsumoto, Naoki Yamamoto, Isao Sakaida – 26 July 2017 – Liver cirrhosis can disturb circadian rhythms, decreasing patient quality of life. Changes in metabolic products in cirrhosis are poorly understood. We evaluated changes in liver metabolism products using a thioacetamide‐induced mouse model of liver cirrhosis exhibiting circadian rhythm disturbance.

Long noncoding RNA TSLNC8 is a tumor suppressor that inactivates the interleukin‐6/STAT3 signaling pathway

Jiwei Zhang, Zhe Li, Longzi Liu, Qifeng Wang, Shengli Li, Di Chen, Zhixiang Hu, Tao Yu, Jie Ding, Jinjun Li, Ming Yao, Shenglin Huang, Yingjun Zhao, Xianghuo He – 26 July 2017 – Long noncoding RNAs can serve as oncogenes or tumor suppressors in human cancer; however, their biological functions and underlying mechanism in hepatocarcinogenesis are largely unknown. Here, we report a novel tumor suppressor long noncoding RNA on chromosome 8p12 (termed TSLNC8) that is frequently deleted and down‐regulated in hepatocellular carcinoma (HCC) tissues.

Interferon lambda 4 rs368234815 TT>δG variant is associated with liver damage in patients with nonalcoholic fatty liver disease

Salvatore Petta, Luca Valenti, Antonino Tuttolomondo, Paola Dongiovanni, Rosaria Maria Pipitone, Calogero Cammà, Daniela Cabibi, Vito Di Marco, Anna Ludovica Fracanzani, Sara Badiali, Valerio Nobili, Silvia Fargion, Stefania Grimaudo, Antonio Craxì – 24 July 2017 – The interferon (IFN) lambda 3/4 (IFNL3/4) locus, influencing innate immunity regulation, has been associated with the severity of hepatitis and fibrosis progression during chronic hepatitis C infection, while contrasting results were reported in nonalcoholic fatty liver disease.

Rapid changes in peripheral lymphocyte concentrations during interferon‐free treatment of chronic hepatitis C virus infection

Eric G. Meissner, Anita Kohli, Jeanette Higgins, Yu‐Jin Lee, Olga Prokunina, David Wu, Cody Orr, Henry Masur, Shyam Kottilil – 24 July 2017 – Treatment of chronic hepatitis C virus (HCV) infection with direct‐acting antivirals results in a rapid decline in viral load and markers of hepatic inflammation, including serum chemokine (C‐X‐C motif) ligand 10 (CXCL10) concentration, which is followed in most cases by a sustained virologic response. Whether parallel changes of significance occur in the cellular composition of peripheral blood is relatively unknown.

Subscribe to